AR126044A1 - Método acelerado para elaborar formulaciones de proteínas liofilizadas - Google Patents

Método acelerado para elaborar formulaciones de proteínas liofilizadas

Info

Publication number
AR126044A1
AR126044A1 ARP220101446A ARP220101446A AR126044A1 AR 126044 A1 AR126044 A1 AR 126044A1 AR P220101446 A ARP220101446 A AR P220101446A AR P220101446 A ARP220101446 A AR P220101446A AR 126044 A1 AR126044 A1 AR 126044A1
Authority
AR
Argentina
Prior art keywords
mtorr
hours
chamber
temperature ranging
formulation
Prior art date
Application number
ARP220101446A
Other languages
English (en)
Spanish (es)
Inventor
Jeff Mcormick
Arnold Mauley
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR126044A1 publication Critical patent/AR126044A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP220101446A 2021-06-01 2022-06-01 Método acelerado para elaborar formulaciones de proteínas liofilizadas AR126044A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163195265P 2021-06-01 2021-06-01

Publications (1)

Publication Number Publication Date
AR126044A1 true AR126044A1 (es) 2023-09-06

Family

ID=82100125

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101446A AR126044A1 (es) 2021-06-01 2022-06-01 Método acelerado para elaborar formulaciones de proteínas liofilizadas

Country Status (14)

Country Link
US (1) US20240368254A1 (enExample)
EP (1) EP4346778A1 (enExample)
JP (1) JP2024521329A (enExample)
KR (1) KR20240016260A (enExample)
CN (1) CN117241787A (enExample)
AR (1) AR126044A1 (enExample)
AU (1) AU2022285665A1 (enExample)
BR (1) BR112023024757A2 (enExample)
CA (1) CA3217210A1 (enExample)
CL (1) CL2023003443A1 (enExample)
IL (1) IL307677A (enExample)
MX (1) MX2023014034A (enExample)
TW (1) TW202313108A (enExample)
WO (1) WO2022256359A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4553432B1 (en) 2023-11-08 2026-04-29 Bachem Holding AG Drying bag and drying system
WO2025099273A1 (en) 2023-11-08 2025-05-15 Bachem Holding Ag Drying bag and drying system

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
CA2409991A1 (en) 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
EP1786918A4 (en) 2004-07-17 2009-02-11 Imclone Systems Inc NEW BISPECIFIC ANTIBODY TETRAVALENT
KR20100052545A (ko) 2007-08-28 2010-05-19 바이오겐 아이덱 엠에이 인코포레이티드 Igf―1r의 다중 에피토프에 결합하는 조성물
EA202090731A1 (ru) * 2017-09-15 2020-06-11 Эмджен Инк. Способ получения лиофилизированного фармацевтического состава на основе терапевтического белка
EP4200333A1 (en) * 2020-08-24 2023-06-28 Amgen Inc. Pharmaceutical formulation comprising a bite, bispecific antibody, and methionine
JP2023541133A (ja) * 2020-09-14 2023-09-28 アムジエン・インコーポレーテツド 凍結乾燥タンパク質製剤を作製する方法

Also Published As

Publication number Publication date
IL307677A (en) 2023-12-01
BR112023024757A2 (pt) 2024-02-15
AU2022285665A1 (en) 2023-10-19
KR20240016260A (ko) 2024-02-06
CA3217210A1 (en) 2022-12-08
US20240368254A1 (en) 2024-11-07
MX2023014034A (es) 2023-12-15
CN117241787A (zh) 2023-12-15
WO2022256359A1 (en) 2022-12-08
AU2022285665A9 (en) 2023-10-26
TW202313108A (zh) 2023-04-01
EP4346778A1 (en) 2024-04-10
JP2024521329A (ja) 2024-05-31
CL2023003443A1 (es) 2024-06-14

Similar Documents

Publication Publication Date Title
AR126044A1 (es) Método acelerado para elaborar formulaciones de proteínas liofilizadas
CO2018011733A2 (es) Composición farmacéutica
AR068507A1 (es) Construcciones vector fluorocarbonado-antigeno para el suministro de antigenos ifluenza
DOP2022000293A (es) Análogos de nucleósido de 1’-ciano y usos de los mismos
AR108936A2 (es) Formulación subcutánea de anticuerpo anti-her2
BR112019009113A2 (pt) formulações de vírus adenoassociado
BR112022021459A2 (pt) Nucleases guiadas por rna, fragmentos ativos e variantes das mesmas e métodos de uso
DK1954308T3 (da) Stabiliseringsmidler til frysetørrede vacciner
PE20190448A1 (es) Formulacion farmaceutica liquida estable
PE20050919A1 (es) Agente endoparasiticida para administracion topica
AR109981A1 (es) Formulación liposomal
CL2025001313A1 (es) Composiciones que contienen enzimas que escinden anticuerpos y métodos de uso de las mismas
MX2024004177A (es) Composiciones inmunogenicas de lnp y metodos de los mismos.
JP2017511816A5 (enExample)
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
MX387019B (es) Formulacion farmaceutica parenteral que contiene acido carglumico.
AR117724A1 (es) Sistema de deposición para el cabello
MX2021008017A (es) Formulaciones de colagenasa y metodos de produccion de las mismas.
CO2022005737A2 (es) Formulación estable de anticuerpo de integrina
AR122428A1 (es) Composiciones farmacéuticas y productos farmacéuticos de interleucina-15 humana heterodimérica (hetil-15)
BR112019005516A2 (pt) novo sítio de inserção do ehv orf70
AR115796A1 (es) Formulaciones estables de temperatura baja de composiciones que contienen inhibidores de ureasa
AR110906A1 (es) Formulaciones y método para la limpieza a baja temperatura de equipos de lechería
PY1961431A (es) Aumento de una producción de alcohol a partir de una levadura que produce una mayor cantidad de proteína crz1 activa
RU2020130402A (ru) Многоразовая композиция торасемида